Medical Device Global Market Access

This episode forecasts the state of medical technology mergers and acquisitions for 2026. We analyze whether the industry will see a return to large, transformative deals driven by the need to fill portfolio gaps in diagnostics, structural heart, and workflow assets, or if valuation discipline and integration risks will ensure the market remains focused on smaller, more selective acquisitions. - Will 2026 mark the return of mega-mergers in the medical device industry? - What portfolio gaps are large medtech companies trying to fill? - Why are diagnostics and structural heart technologies so attractive for acquisition? - How do high valuations and integration risks impact M&A decisions? - What role will regulatory scrutiny play in future deals? - Are smaller 'tuck-in' acquisitions a safer bet for growth? - How can companies prepare their regulatory strategy for post-merger integration? Successful M&A is just the first step; integrating a new portfolio and achieving global market access is the next challenge. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, ensuring your expanded product line meets international compliance. Our experts develop efficient regulatory strategies and use advanced AI to compile technical dossiers, streamlining submissions across 30+ markets. Whether you're a startup or a multinational enterprise navigating post-acquisition complexities, we provide the local expertise and data tools to accelerate your global growth. Contact us at [email protected], visit https://pureglobal.com, or explore our free AI tools at https://pureglobal.ai.

This episode explores the significant impact that rising tariffs and supply-chain nationalism are projected to have on the medical technology industry by 2026. We dissect the four primary strategic responses available to MedTech firms: relocating production, diversifying sourcing networks, increasing prices, or absorbing shrinking profit margins. The host explains how these choices will be influenced by device category, reimbursement landscapes, and specific geopolitical tensions, urging companies to proactively plan for a new era of manufacturing and market access. Key Questions: - What is “supply-chain nationalism” and why is it a major threat to MedTech? - By 2026, how will new tariffs disrupt established manufacturing models? - Is relocating production (reshoring) a viable option for most device manufacturers? - How can companies redesign sourcing networks to mitigate geopolitical risks? - Will healthcare systems accept price increases driven by supply chain costs? - What happens to innovation if companies are forced to absorb lower profit margins? - Which device categories are most vulnerable to these global shifts? Navigating the challenges of tariffs and supply chain realignment demands a proactive, global regulatory strategy. Pure Global helps MedTech and IVD companies navigate this complexity. Our experts develop efficient pathways for regulatory approval and market access in over 30 countries, using advanced AI to compile technical dossiers and monitor regulatory changes. Whether you're assessing new markets to diversify your footprint or ensuring continuous compliance amidst shifting trade policies, we provide the local expertise and data-driven tools to secure your global presence. Contact us at [email protected], visit https://pureglobal.com, or explore our free AI tools at https://pureglobal.ai.

This episode examines the immense pressures facing medical device manufacturers from Europe's Medical Device Regulation (MDR) and In-Vitro Diagnostic Regulation (IVDR) leading up to 2026. We explore the two potential outcomes: widespread "portfolio pruning" and market consolidation due to high compliance costs and Notified Body bottlenecks, or the successful reduction of these pressures by regulators before essential devices are removed from the market. Key Questions: - What are the biggest challenges manufacturers face with the EU MDR and IVDR transition? - Why is the year 2026 so critical for the European MedTech market? - What is "portfolio pruning" and how could it affect patient care? - Will the shortage of Notified Bodies lead to a market crisis? - How are companies deciding which products to keep and which to discontinue? - Could MDR and IVDR compliance costs force smaller companies out of the market? - What steps can be taken to reduce the regulatory bottlenecks in Europe? - Is industry consolidation an inevitable outcome of these new regulations? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies navigating complex landscapes like Europe's MDR/IVDR transition. We combine local expertise with advanced AI to streamline global market access, developing efficient regulatory strategies and compiling technical dossiers. Whether you are managing portfolio decisions or seeking new market entry, our team can help. Visit us at https://pureglobal.com, contact [email protected], or explore our FREE AI tools and database at https://pureglobal.ai to accelerate your global reach.

This episode delves into the upcoming 2026 Medical Device User Fee Amendments (MDUFA VI) negotiations and their profound impact on the U.S. medtech landscape. We explore how these negotiations will influence FDA review predictability, staffing stability, and fee structures, and what this means for the strategic planning of medical device companies, particularly startups and smaller innovators. - What are the Medical Device User Fee Amendments (MDUFA)? - Why are the 2026 negotiations critical for medtech innovation? - How does FDA review predictability affect a small company's fundraising and launch schedule? - What is the link between user fees and FDA staffing challenges? - Will the new MDUFA fee structure help or hinder smaller medtech firms? - How should companies adjust their regulatory strategy in anticipation of MDUFA VI? - What performance goals will the industry push for in the next MDUFA cycle? Navigating the U.S. FDA and other global markets requires expert strategy. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, leveraging local expertise and advanced AI tools to streamline market access. From developing efficient regulatory strategies and pre-submission activities for the FDA to acting as your local representative in over 30 markets, we ensure you can launch and maintain your products efficiently. Our technology-driven approach enhances accuracy and speed, helping you stay ahead. Visit our website at https://pureglobal.com/, contact us at [email protected], or explore our FREE AI tools and database at https://pureglobal.ai.

This episode explores the prediction that by 2026, the primary obstacle for AI medical devices will shift from technical validation to securing financial reimbursement. We discuss why clear payment pathways, understandable coding logic, and compelling health economic outcome evidence are becoming more critical than algorithmic accuracy for commercial success. This is a crucial look at the strategic planning required to navigate the evolving landscape of AI MedTech market access. Key Questions: - Why is technical accuracy no longer enough for AI medical device success? - What are the biggest reimbursement challenges facing AI MedTech in 2026? - How do payment pathways and coding logic determine commercial viability? - What kind of outcome evidence do health systems and payers actually require? - Is your AI device strategy prepared for the post-approval reimbursement bottleneck? - How can you build a reimbursement strategy from day one of product development? - What role does health economics play in market access for advanced AI tools? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies. We develop efficient pathways for regulatory approval and help you identify the best markets for expansion by leveraging your existing approvals. Our experts use advanced AI to compile and submit technical documents, ensuring you can navigate complex global requirements. Whether you're a startup or a multinational, we provide scalable solutions to get your innovation to market faster. Contact us at [email protected], visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode explores the future of the diabetes technology market, examining the critical tension between rapid innovation and foundational regulatory challenges. We analyze whether the competitive landscape leading into 2026 will be defined more by exciting advancements like fully closed-loop systems and longer-wear sensors, or by persistent issues such as product recalls, complaint handling, and software reliability. We discuss how market leaders must master both cutting-edge development and stringent post-market compliance to succeed. Key Questions: - How are fully closed-loop artificial pancreas systems set to redefine diabetes care? - What makes longer-wear CGM sensors a major competitive battleground? - Why have recalls and complaint handling become such significant hurdles for leading MedTech firms? - Is software reliability the most critical, yet overlooked, factor in automated insulin delivery? - How can manufacturers balance groundbreaking innovation with the demands of global regulators? - What will separate the market leaders from the followers in the diabetes tech space by 2026? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, helping you navigate these complex challenges. Our experts develop efficient pathways for regulatory approval, using advanced AI to compile and submit technical dossiers for devices, including complex Software as a Medical Device (SaMD). We also manage post-market surveillance and continuous regulatory monitoring to ensure you not only enter the market but maintain your presence securely. Let us help you balance innovation with compliance. Contact Pure Global at [email protected], visit us at https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

This episode explores the transformative potential of AI-enabled imaging and ultrasound tools designed for non-experts, set to reshape diagnostics by 2026. We dissect the four emerging business models—hardware, workflow software (SaMD), remote interpretation, and population-scale screening—and analyze the unique global regulatory, data privacy, and market access challenges associated with each. Discover which strategies are best positioned to succeed in this new era of decentralized healthcare. Key Questions: - How will AI empower non-specialists to use advanced ultrasound and imaging tools by 2026? - What are the four primary business models emerging from this technology shift? - What specific regulatory hurdles exist for AI-enabled hardware versus Software as a Medical Device (SaMD)? - How do data privacy laws like GDPR and HIPAA impact remote interpretation services? - What are the unique market access challenges for population-scale screening programs? - Why is a unified global regulatory strategy essential for success in this new market? - Which business model is best positioned to capture value by navigating these complexities? Navigating the complex regulatory landscape for AI-driven medical devices is critical. Pure Global specializes in helping innovative MedTech and IVD companies commercialize their products globally. We develop efficient regulatory strategies for complex technologies like Software as a Medical Device (SaMD) and AI-enabled hardware, helping you overcome market access hurdles in over 30 countries. Our integrated approach combines local expertise with advanced AI tools to streamline technical dossier submission and ensure ongoing compliance. To accelerate your global expansion, contact Pure Global at [email protected], visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode explores the transformative shift in the surgical robotics market, predicting a move away from a single-player monopoly by 2026. We analyze the impact of new FDA-approved platforms from giants like Medtronic and Johnson & Johnson, the rise of specialization in fields such as orthopedics and cardiac surgery, and how competition is now being driven by factors like price, workflow efficiency in ambulatory surgical centers, and the integration of artificial intelligence. - Will the surgical robotics market remain dominated by one giant in 2026? - How are new FDA approvals for Medtronic’s Hugo and J&J’s Ottava changing the competitive landscape? - Is specialization in spine, cardiac, and microsurgery the new frontier for robotic platforms? - How do smaller, modular robots create new opportunities in ambulatory surgical centers (ASCs)? - What role does Artificial Intelligence (AI) play in differentiating the next generation of surgical robots? - Are high costs and complex training no longer significant barriers to robotic surgery adoption? - What does increased competition mean for innovation, hospital procurement, and patient care? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access with local expertise and advanced AI tools. From developing regulatory strategy and compiling technical dossiers to acting as your in-country representative in over 30 markets, we accelerate your path to commercialization. Our AI and data tools offer powerful market research capabilities, helping you identify the best regions for expansion. Whether you are a startup or a multinational, Pure Global provides efficient, technology-driven solutions for your global ambitions. Contact us at [email protected], visit https://pureglobal.com/, or explore our FREE AI tools at https://pureglobal.ai/.

This episode examines how U.S. FDA regulations have repositioned cybersecurity as a core feature of medical devices. We discuss the impact of the Consolidated Appropriations Act of 2023 and the FDA's "Refuse to Accept" policy, exploring why a secure architecture, a Software Bill of Materials (SBOM), and robust incident response plans are now critical for regulatory approval, hospital trust, and commercial success heading into 2026. - What new authority did the FDA gain over medical device cybersecurity in 2023? - Why is a Software Bill of Materials (SBOM) now a mandatory part of FDA submissions? - How has "secure by design" shifted from a best practice to a regulatory necessity? - What are the essential components of a compliant post-market cybersecurity plan? - How will a device's security posture directly influence hospital purchasing decisions by 2026? - What is the FDA's "Refuse to Accept" policy for cybersecurity? - How can manufacturers prepare their technical dossiers for these new requirements? Pure Global offers end-to-end consulting for MedTech and IVD companies, helping you navigate complex regulatory landscapes like the FDA's new cybersecurity rules. Our experts develop efficient regulatory strategies and use advanced AI to compile and submit technical dossiers that meet these stringent new standards. We act as your local representative to ensure continuous compliance and monitor regulatory changes that could impact your market access. Let us help you get to market faster. Contact us at [email protected], visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode delves into the U.S. FDA's upcoming Total Product Life Cycle (TPLC) Advisory Program, known as TEMPO, set to launch in 2026. We explore its potential to revolutionize the pathway for digital health and chronic-care medical devices by integrating payers early in the regulatory process. We analyze whether TEMPO can successfully bridge the gap between regulatory approval and reimbursement, or if manufacturers will still face significant hurdles in proving value to secure market access. - What is the FDA's TEMPO pilot program launching in 2026? - How does TEMPO aim to connect regulatory approval with payer reimbursement? - Why do many approved digital health devices struggle to get paid for by insurers? - What specific challenges does the program target for chronic-care device makers? - Could TEMPO reduce the time and cost of bringing new MedTech to market? - What are the potential limitations or reasons for skepticism about the pilot's success? - How can manufacturers prepare their evidence strategy for both the FDA and payers? Navigating the complex path from regulatory approval to reimbursement requires a robust strategy. Pure Global offers end-to-end consulting for MedTech and IVD companies, developing efficient pathways for approval that consider payer requirements from the start. We use advanced AI to compile and manage technical dossiers and provide continuous regulatory monitoring to keep you ahead of changes like the TEMPO pilot. Whether you're a startup or a multinational, we help you identify the best markets and build the evidence needed for successful global access. Contact Pure Global at [email protected], visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

This episode explores the evolving regulatory landscape for digital health, focusing on the U.S. FDA's projected stance in 2026. We dissect the critical line between general wellness wearables and regulated medical devices, analyzing how advanced features like blood pressure monitoring, sleep analysis, and AI coaching are forcing new regulatory clarity. We delve into the importance of a product's intended use, its marketing claims, and the level of risk it presents to the user as key factors in the FDA's classification process. - Where does the FDA draw the line between a wellness wearable and a medical device in 2026? - How do the January 2026 FDA guidance documents redefine "general wellness" for low-risk devices? - Can a wearable that monitors blood pressure be sold without FDA clearance? - What separates an AI-powered wellness coach from regulated Clinical Decision Support software? - Which product claims will automatically classify a digital health app as a medical device? - How does a company's marketing language impact its regulatory obligations? - What are the winning strategies for companies in the wearable technology space? Pure Global offers comprehensive regulatory consulting for MedTech and IVD firms, simplifying global market access. We leverage local expertise across 30+ markets and advanced AI tools to develop efficient regulatory strategies, manage technical dossiers, and ensure post-market compliance. Whether you are a startup or a multinational, our end-to-end solutions help you navigate complex landscapes, from initial market research to gaining and maintaining registration for your devices. Let us be your partner in accelerating your global expansion. Contact us at [email protected], visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

This episode explores the FDA's expected regulatory landscape for AI-enabled medical devices in 2026. We discuss the critical shift from pre-market assessment to a total product lifecycle approach, focusing on the non-negotiable requirements for real-world performance monitoring and Predetermined Change Control Plans (PCCPs). Learn what will separate scalable, approvable medtech platforms from demo-grade algorithms that cannot withstand long-term regulatory scrutiny. - How will the FDA's definition of 'safe and effective' for AI devices change by 2026? - What is a Predetermined Change Control Plan (PCCP) and why will it be mandatory? - Why is real-world performance monitoring becoming more critical than initial pilot data? - What is 'algorithmic drift' and how must manufacturers plan to manage it? - How does clinical workflow integration impact the regulatory viability of an AI device? - What separates a sustainable medtech platform from a simple AI algorithm? - How can you build a lifecycle governance strategy that meets future FDA expectations? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access with local expertise and advanced AI tools. From developing a regulatory strategy and compiling your technical dossier to acting as your local representative in over 30 markets, we cover the entire product lifecycle. Our technology-driven approach ensures efficiency and accuracy, helping you navigate complex requirements for market approval and post-market surveillance. To access new markets faster and ensure ongoing compliance, contact Pure Global at [email protected], visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode delves into the top health technology hazard: the logistical challenges of communicating recalls and firmware updates for home-use medical devices. We explore the fragmented communication chain from manufacturer to patient, the difficulties in executing physical returns and software corrections for non-clinical users, and the regulatory definition of a firmware update as a recall. - Why are home-use device recalls considered the #1 medical tech hazard? - What makes communicating with patients so different from communicating with hospitals? - How does the fragmented supply chain prevent manufacturers from reaching end-users? - Are critical firmware or software updates considered a medical device recall by the FDA? - What were the key communication failures in the massive 2021 CPAP machine recall? - What are the logistical challenges of physically retrieving thousands of devices from patients' homes? - How can companies ensure non-technical users apply critical updates correctly? - What is the Unique Device Identification (UDI) system and how might it solve this problem? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access with local expertise and advanced AI. Our services cover the entire product lifecycle, from initial regulatory strategy and technical dossier submission to post-market surveillance and continuous regulatory monitoring. By acting as your local representative in over 30 markets, we ensure your products not only get to market but also maintain compliance in complex, ever-changing regulatory landscapes. Visit us at https://pureglobal.com, contact [email protected], or explore our FREE AI tools and database at https://pureglobal.ai.

The rise of sophisticated 3D-printed counterfeit medical devices presents a grave threat to patient safety and brand integrity. This episode delves into the escalating battle between counterfeiters and MedTech manufacturers, exploring the cutting-edge technologies being deployed to secure the global supply chain. We examine how solutions like blockchain and invisible marking technologies are becoming essential for verifying product authenticity, ensuring traceability, and complying with increasingly strict international regulations. Key Questions: - How has 3D printing revolutionized the counterfeit medical device industry? - What are the most significant risks counterfeit products pose to patients? - How does blockchain technology create a secure and traceable supply chain? - What are invisible markings, and how do they help verify a product's authenticity? - Why are these expensive technologies becoming a necessary investment for manufacturers? - How do anti-counterfeiting measures align with regulatory requirements like the FDA and EU UDI systems? - What is the impact of counterfeiting on a MedTech company's brand and market access? Navigating the complexities of global supply chain security and regulatory compliance is a significant challenge. Pure Global offers end-to-end consulting for MedTech and IVD companies, leveraging local expertise and advanced AI to streamline global market access. From developing regulatory strategies and managing technical submissions to ensuring post-market surveillance, Pure Global acts as your local representative in over 30 markets. Our technology-driven approach ensures efficiency and accuracy in securing your product's journey to market. Visit https://pureglobal.com/, contact us at [email protected], or explore our FREE AI tools and database at https://pureglobal.ai to accelerate your expansion.

This episode explores the rise of "self-healing" supply chains, an AI-driven solution designed to combat the logistical nightmares caused by modern geopolitical tensions. We examine how these automated networks use predictive analytics to anticipate disruptions, autonomously reroute critical medical device shipments, and maintain regulatory compliance in a volatile world. This shift from reactive to proactive logistics is becoming a necessity for ensuring patient safety and building resilient MedTech operations. - What is a "self-healing" supply chain and why is it critical for MedTech now? - How do geopolitical tensions directly threaten the delivery of medical devices? - Can AI really predict a stockout before it happens? - How do automated logistics networks make decisions without human intervention? - What are the regulatory compliance challenges of an autonomous supply chain? - How does this technology ensure patient safety during a global crisis? - What data sources fuel these predictive AI models? - How is Unique Device Identification (UDI) managed in a dynamic supply network? Facing complex global supply chains and regulatory hurdles? Pure Global offers end-to-end consulting for MedTech and IVD companies, leveraging advanced AI and a network of local experts in over 30 markets. We develop efficient regulatory strategies, manage technical submissions, and provide continuous monitoring to ensure your products stay compliant. Our technology-driven approach streamlines global market access, helping you navigate volatility with confidence. Let us be your partner in building a resilient global presence. Visit us at https://pureglobal.com, contact [email protected], or explore our FREE AI tools and database at https://pureglobal.ai.

This episode explores the growing regulatory pressure on medical device manufacturers to mitigate algorithmic bias in AI-powered diagnostics. We discuss why "black box" algorithms are facing scrutiny, what bodies like the FDA are now requiring as evidence of equitable performance, and the significant risks of failing to address bias, including market withdrawal. - What is "algorithmic bias" in the context of AI medical devices? - Why are regulators demanding transparency in AI models? - What specific evidence must manufacturers provide to prove their AI performs equitably across diverse populations? - How has FDA guidance on AI bias evolved since 2021? - What are the financial and reputational risks of a biased diagnostic tool? - How can you integrate bias mitigation into your product's entire lifecycle? - What documentation is now essential for your technical file and marketing submission? - Can failure to address AI bias lead to a product recall? Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies navigating complex challenges like AI bias. Our experts develop robust regulatory strategies and use advanced AI tools to efficiently compile technical dossiers that meet the stringent requirements of global authorities like the FDA and EU. We help you demonstrate equitable performance and secure market access for your innovative devices. Ensure your product is ready for global markets by contacting us at [email protected] or visiting https://pureglobal.com. Explore our free AI-powered regulatory tools and database at https://pureglobal.ai.

This episode explores the strategic pivot required for MedTech companies as over 500 surgical procedures shift to Ambulatory Surgery Centers (ASCs) by 2026. We break down why traditional hospital-focused sales models are failing in the high-efficiency ASC environment and outline the new logistics, pricing, and value propositions needed to succeed in this rapidly growing market. - Why is the 2026 procedural shift to ASCs a critical challenge for MedTech sales teams? - How do purchasing decisions in an ASC differ from those in a hospital? - What common mistakes do hospital-focused sales teams make when approaching ASCs? - What are the essential logistics and pricing models required for the ASC environment? - How can you tailor your value proposition to appeal directly to surgeon-owners? - Is your company prepared for the addition of over 500 procedures to the ASC-approved list? - What specific strategies will win in the competitive Ambulatory Surgery Center market? Pure Global offers end-to-end regulatory consulting to help MedTech companies capitalize on market shifts like the move to ASCs. Our experts develop efficient regulatory strategies and conduct market research to identify the best pathways for expansion. By combining local expertise in over 30 markets with advanced AI tools, we streamline the process of getting your product approved and ready for sale. Whether you're a startup or a multinational, we help you navigate complex environments and optimize your product portfolio for new opportunities. Contact us at [email protected] or visit https://pureglobal.com. Explore our free AI tools and database at https://pureglobal.ai.

This episode explores the pivotal shift in hospital procurement from traditional capital expenditures (CapEx) to subscription-based Device-as-a-Service (DaaS) models. We analyze why this change is occurring and detail its disruptive impact on medical device manufacturers, covering critical adjustments required in revenue recognition, sales compensation, customer relationships, and even product design to thrive in this new service-oriented landscape. Key Questions - Why are hospitals moving away from large, upfront equipment purchases? - What is included in a "Device-as-a-Service" (DaaS) contract? - How does subscription billing fundamentally change revenue recognition for MedTech companies? - What new sales commission structures are needed for a recurring revenue model? - How does the manufacturer-customer relationship evolve from transactional to a long-term partnership? - What are the implications for product design and durability in a DaaS model? - Can subscription models create a competitive advantage in new international markets? Navigating disruptive commercial models requires a forward-thinking global strategy. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, helping you develop efficient pathways for market access and identify the best countries for expansion. Our unique combination of local expertise and advanced AI tools streamlines the creation of technical dossiers and keeps you ahead of regulatory changes. Let us help you turn market shifts into opportunities. Contact Pure Global at [email protected], visit us at https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode delves into the critical reimbursement gap facing innovative medical devices in the United States. We explore why FDA Breakthrough Device designation doesn't guarantee Medicare payment, the financial "valley of death" this creates for MedTech startups, and how the proposed "Ensuring Patient Access to Critical Breakthrough Products Act" aims to provide a vital four-year bridge of temporary coverage. - What is the FDA's Breakthrough Devices Program? - Why does FDA approval not automatically lead to Medicare reimbursement? - What is the "reimbursement valley of death" for MedTech innovators? - How does the evidence required by the FDA differ from that required by CMS? - What was the MCIT rule and why was its 2021 repeal significant? - What is the "Ensuring Patient Access to Critical Breakthrough Products Act"? - How does the proposed four-year transitional coverage period work? - Why is this legislation critical for medical innovation and patient access? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. We develop efficient pathways for regulatory approval, leveraging advanced AI to compile and submit technical dossiers that minimize rejections. Our experts act as your local representative in over 30 markets, helping you identify the best regions for expansion and ensuring your innovative products reach patients faster. Whether you are a startup or a multinational enterprise, our technology-driven solutions are tailored to your needs. Contact us at [email protected], visit https://pureglobal.com, or explore our FREE AI tools at https://pureglobal.ai.

This episode delves into the growing use of agentic AI for drafting complex regulatory dossiers like FDA 510(k)s and EU Technical Files. We explore the paradox where AI's speed in drafting is offset by a massive bottleneck: the intensive, time-consuming process of human-in-the-loop validation. Discover why this crucial verification step is non-negotiable and how it's reshaping the role of regulatory professionals, preventing the promised acceleration to market. Key Questions: - What is "agentic AI" and how is it changing MedTech regulatory submissions? - Why is the dream of fully automated dossier creation still out of reach? - What is the "human-in-the-loop" validation bottleneck and why is it critical? - How can you leverage AI's power for submissions without compromising on compliance? - What are the legal and practical risks of over-relying on AI for regulatory files? - Is your regulatory team prepared for the new skills needed to manage AI tools? - How does a balanced "co-pilot" approach to AI optimize your submission strategy? Pure Global helps MedTech and IVD companies navigate these modern regulatory challenges. We combine deep local expertise with advanced AI tools to streamline your global market access. Our services assist in developing efficient regulatory strategies and compiling technical dossiers, ensuring accuracy while leveraging technology to accelerate processes. Instead of getting bogged down by validation, let our experts and AI-powered platforms manage your submissions efficiently across more than 30 markets. Contact us at [email protected], visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai to learn more.

This episode explores the growing threat of 'digital darkness'—total network outages caused by cyberattacks—and its impact on the medical device industry. We delve into the heightened scrutiny from regulatory bodies like the FDA and under the EU MDR, focusing on new requirements for manufacturers to prove their devices can function safely and effectively offline. We discuss key strategies for building cybersecurity resilience, from design and risk assessment to post-market surveillance. Key Questions - What is "digital darkness" and why is it a top concern for hospitals? - How are the FDA and EU regulators changing their cybersecurity requirements for medical devices? - What must manufacturers now demonstrate about their device's offline capabilities? - Why has a Software Bill of Materials (SBOM) become a critical submission document? - What are effective strategies for designing devices that are resilient to network failure? - How does post-market surveillance play a role in managing cybersecurity risks? - What are the consequences for manufacturers who fail to meet these new standards? Pure Global provides comprehensive regulatory consulting for MedTech and IVD companies, ensuring your products meet complex global standards, including cybersecurity. Our experts develop efficient regulatory strategies and use advanced AI to compile technical dossiers, helping you navigate demanding requirements from bodies like the FDA and EU. We act as your local representative in over 30 markets, managing the entire lifecycle from initial submission to post-market surveillance. Let us help you achieve faster global market access. Contact us at [email protected], visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

This episode explores the pivotal shift from traditional clinical trial data to the increasing demand for continuous Real-World Evidence (RWE) for medical devices. We delve into why global regulators and payers now require robust post-market data to prove a device's long-term safety, effectiveness, and value. We also unpack the significant infrastructure and analytical challenges that MedTech companies face in building a compliant and effective RWE program. Key Questions: - What is the difference between Real-World Data (RWD) and Real-World Evidence (RWE)? - Why are traditional clinical trials no longer sufficient for market approval and reimbursement? - How do new regulations like the EU MDR impact post-market data collection requirements? - What specific evidence are payers looking for to determine a device's cost-effectiveness? - What are the main challenges companies face when building an RWE generation system? - How can a strong RWE strategy provide a competitive advantage? As regulatory demands for Real-World Evidence intensify, having a proactive strategy is essential. Pure Global helps MedTech and IVD companies design and implement robust post-market surveillance and data analysis programs. Our blend of local regulatory expertise and advanced AI tools simplifies the process of gathering, analyzing, and submitting the evidence needed to maintain and expand global market access. We turn your post-market obligations into a strategic advantage. To learn more about our services, visit us at https://pureglobal.com/, contact [email protected], or explore our FREE AI tools and database at https://pureglobal.ai.

This episode delves into the EU's new Artificial Intelligence Act and its significant impact on medical device manufacturers. We explore the "high-risk" classification for most AI-driven medical devices, the new compliance obligations that run parallel to existing MDR/IVDR requirements, and the critical timelines manufacturers must meet. We break down the challenges and strategies for navigating this dual regulatory framework, from data governance to human oversight. - What is the EU AI Act and why is it critical for MedTech companies? - How are AI-powered medical devices classified under this new regulation? - What are the new, specific compliance requirements beyond MDR and IVDR? - How does the conformity assessment process work for both the AI Act and MDR/IVDR? - Are you required to get two separate certifications? - What is the key compliance deadline that all manufacturers must have on their calendar? - How should you prepare your Quality Management System and technical documentation for this dual framework? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access with local expertise and advanced AI tools. We act as your local representative in over 30 markets, developing efficient regulatory strategies to get your products approved faster. Our AI-powered platforms help compile and manage technical dossiers for seamless submissions to authorities in the EU and beyond. Whether you're a startup or a multinational, we provide tailored solutions for market access and continuous compliance. Contact us at [email protected], visit https://pureglobal.com/, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode breaks down the FDA's final rule transitioning the Quality System Regulation (21 CFR Part 820) to the ISO 13485-aligned Quality Management System Regulation (QMSR). We cover the February 2, 2026, compliance deadline, the key differences and retained FDA requirements, and the strategic steps medical device manufacturers must take to harmonize their global quality documentation and ensure a seamless transition. - What is the FDA's new Quality Management System Regulation (QMSR)? - When is the mandatory deadline to transition from QSR to QMSR? - How does the new rule align with the global standard ISO 13485? - Why is simply having an ISO 13485 certificate not enough for compliance? - Which specific U.S. requirements are being kept in the new QMSR? - What are the biggest challenges in harmonizing global quality documents? - What is the first step your company should take to prepare for the 2026 deadline? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies. Navigating the FDA's transition to the QMSR while managing global registrations requires expert strategy. We develop efficient pathways for regulatory approval, using advanced AI to compile and manage technical dossiers that meet both new QMSR and international standards. Our local experts in over 30 markets ensure your quality systems are compliant globally. Let us streamline your transition and accelerate your global market access. Contact Pure Global at [email protected], visit us at https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode delves into the critical capacity crisis among Notified Bodies under the EU's Medical Device Regulation (MDR). We explore how the stringent requirements of the MDR, combined with a reduction in the number of designated Notified Bodies, have created a massive bottleneck for certifying new and legacy medical devices. We discuss the significant risk this poses to manufacturers, who face the possibility of their products being forced off the market as old certificates expire, and examine the European Commission's legislative response to extend the transition deadlines. - What is the EU MDR Notified Body capacity crisis? - Why are there multi-year delays for device certification in Europe? - How did the transition from the MDD to the MDR create a market bottleneck? - What are the crucial deadlines of May and September 2024 for legacy devices? - Could your medical device be forced off the EU market due to expiring certificates? - What steps did the European Commission take to prevent a widespread device shortage? - How does the risk class of your device affect its new transition deadline? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies. We streamline global market access with local expertise and advanced AI, helping you navigate complex challenges like the EU MDR. Our services include developing efficient regulatory strategies, compiling technical dossiers with AI, and acting as your local representative in over 30 markets. We help you meet critical deadlines and maintain market presence. For support with your global expansion, contact us at [email protected], visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode dives into one of the most significant challenges facing medical device manufacturers in 2026—the mandatory EUDAMED registration deadline. We break down what the May 2026 milestone means, the complexities of uploading technical and Unique Device Identification (UDI) data, and the critical steps companies must take now to avoid being locked out of the European Union market. Key Questions: - What is the EUDAMED and why is it critical for EU market access? - When is the final deadline for mandatory EUDAMED registration? - What specific data, including UDI information, must be uploaded? - What are the consequences of failing to meet the 2026 EUDAMED requirements? - How does the new database impact post-market surveillance and transparency? - What are the biggest data management challenges manufacturers face with this new system? - How can you prepare your technical dossiers for a seamless EUDAMED submission? Struggling to prepare for complex regulatory shifts like the EUDAMED deadline? Pure Global offers end-to-end consulting for MedTech and IVD companies, streamlining global market access. Our experts develop efficient regulatory strategies and use advanced AI to compile and submit technical dossiers, ensuring compliance with evolving standards. We act as your local representative in over 30 markets, including the EU, managing the entire registration process. To secure your market presence and navigate deadlines with confidence, visit us at https://pureglobal.com, contact [email protected], or explore our FREE AI tools and database at https://pureglobal.ai.

This episode provides a detailed breakdown of the medical device registration fees charged by Singapore's Health Sciences Authority (HSA). We cover the standard application fee and the specific evaluation costs for Class B, Class C, and Class D devices. The host explains how different evaluation routes—such as Full, Abridged, Expedited, and Immediate—impact the final cost and how leveraging prior approvals from reference agencies can lead to significant savings. - What are the latest HSA registration fees for medical devices in Singapore as of August 2024? - How do evaluation costs differ between Class B, Class C, and Class D devices? - What is the difference in cost between a Full, Abridged, and Expedited evaluation route? - Can prior approval from the US FDA or a European Notified Body reduce my Singapore registration fees? - What is the standard application fee for all device classes? - How can a strategic approach to registration save thousands of dollars per application? - What costs are not included in the official HSA fees? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies looking to enter markets like Singapore. Our team of local experts, combined with advanced AI and data tools, can help you develop the most efficient regulatory strategy, prepare your technical dossier, and act as your local representative. We streamline the global market access process, helping you navigate complex fee structures and regulatory requirements to get your product to market faster. For more information, visit us at https://pureglobal.com, contact [email protected], or explore our FREE AI tools and database at https://pureglobal.ai.

This episode provides a detailed overview of Singapore's mandatory Good Distribution Practice for Medical Devices (GDPMDS) certification. We explore the governing standard, SS 620:2016, and explain why it is an essential requirement enforced by the Health Sciences Authority (HSA) for any company seeking to import or wholesale medical devices in this key Asian market. Learn about the core components of the standard, from quality management systems to traceability and storage, to ensure your supply chain is compliant. - What is GDPMDS and why is it mandatory for market access in Singapore? - How does the SS 620:2016 standard impact medical device importers and wholesalers? - What are the key pillars of a compliant Quality Management System under GDPMDS? - Why is traceability a critical component of Singapore's distribution requirements? - What role does the Health Sciences Authority (HSA) play in enforcing these regulations? - Are there specific requirements for storage, stock rotation, and handling recalls? Pure Global offers end-to-end regulatory consulting to streamline global market access for MedTech and IVD companies. We act as your local representative in over 30 markets, including Singapore, developing efficient regulatory strategies and using advanced AI to compile technical dossiers. This ensures you meet critical requirements like GDPMDS for faster approvals. Our experts manage the entire process, from initial submission to post-market surveillance, ensuring your continued compliance. Visit us at https://pureglobal.com, contact [email protected], or explore our FREE AI tools and database at https://pureglobal.ai to accelerate your market entry.

This episode provides a detailed guide to the three types of medical device dealer licenses required by Singapore's Health Sciences Authority (HSA): manufacturer, importer, and wholesaler. We clarify the specific activities each license permits and highlight the critical, non-negotiable requirement for a compliant Quality Management System (QMS), referencing key standards like GDPMDS and ISO 13485. - What are the three types of dealer licenses for medical devices in Singapore? - If I import a device, do I automatically have the right to sell it wholesale? - What is the difference between an importer's and a wholesaler's license under HSA? - What Quality Management System (QMS) certifications does the HSA accept? - Is an ISO 13485 certificate always sufficient for a Singapore dealer license application? - What is GDPMDS and why is it important for Singapore market access? - Do manufacturers in Singapore need a separate license to sell their own products? - Are there any license exemptions for low-risk medical devices? Navigating complex regulations like Singapore's dealer licensing is where Pure Global excels. We offer end-to-end regulatory consulting for MedTech and IVD companies, acting as your local representative and using advanced AI to streamline dossier submission. Our experts ensure your Quality Management System meets HSA standards, paving a smoother path to market entry. Whether you're a startup or a multinational, we can help you access over 30 global markets faster. Contact Pure Global at [email protected], visit us at https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode delves into a key regulatory pathway in Singapore for low-risk medical devices. We explore the Health Sciences Authority's (HSA) exemption from product registration for Class A non-sterile devices, a crucial topic clarified by guidance from June 1, 2022. We detail the specific requirements that are waived, as well as the crucial obligations that remain, such as dealer licensing and post-market surveillance. This is essential listening for any MedTech company looking to enter the Singaporean market efficiently with a low-risk product portfolio. - What is Singapore's Class A medical device registration exemption? - Does my low-risk, non-sterile device need to be registered with the HSA? - If product registration is not required, what licenses do I still need? - What are the post-market responsibilities for exempt devices in Singapore? - Who is responsible for correctly classifying a medical device to qualify for the exemption? - How can this pathway accelerate my entry into the Singaporean market? Pure Global streamlines global market access for MedTech and IVD companies. For Singapore, we act as your local representative, manage dealer licensing, and ensure your regulatory strategy leverages pathways like the Class A exemption. Our experts, supported by advanced AI tools, help you compile technical dossiers and manage post-market compliance, ensuring a fast and compliant entry. Access over 30 markets with our end-to-end solutions. Visit us at https://pureglobal.com, contact [email protected], or explore our FREE AI tools and database at https://pureglobal.ai.

This episode provides a detailed guide on using the ASEAN Common Submission Dossier Template (CSDT) for medical device registration in Singapore. We cover the structure of the CSDT, specific documentation required by Singapore's Health Sciences Authority (HSA), and how requirements vary based on device risk classification, ensuring you have the information to prepare a successful submission. - What is the ASEAN Common Submission Dossier Template (CSDT)? - How does the CSDT streamline medical device registration in Southeast Asia? - What are the essential components of a CSDT technical file for Singapore's HSA? - How do documentation requirements differ for Class A, B, C, and D devices in Singapore? - What are the common pitfalls to avoid when preparing your submission? - Why is a robust risk management file compliant with ISO 14971 crucial for HSA approval? - What specific labeling requirements must be met for the Singaporean market? Need to navigate the complexities of global markets like Singapore? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies. We leverage local expertise in over 30 markets and advanced AI tools to streamline your market access strategy, technical dossier preparation, and registration submissions. Our services ensure your product meets all local requirements, from initial strategy to post-market surveillance. Let us be your local representative and partner in global expansion. Contact Pure Global at [email protected], visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode explores Singapore's Health Sciences Authority (HSA) abridged evaluation route, a streamlined pathway for medical device registration. We detail how manufacturers can leverage prior approvals from five major reference agencies—including the US FDA and EU Notified Bodies—to accelerate market access for Class B, C, and D devices in this key ASEAN hub. - What are Singapore's five reference regulatory agencies for medical devices? - How can a US FDA approval or EU CE Mark speed up your registration in Singapore? - What is the HSA's abridged evaluation route and how does it work? - Which medical device classes are eligible for this streamlined process? - What specific documentation is required to utilize the abridged pathway? - Does using a reference approval guarantee registration with the HSA? - Why is Singapore considered a strategic first market for expanding into the ASEAN region? Pure Global offers end-to-end consulting for MedTech and IVD companies, streamlining global market access with a powerful combination of local expertise and advanced AI tools. We develop efficient regulatory strategies and act as your local representative to get your products approved and ready for sale in over 30 markets, including Singapore. Our experts use AI to efficiently compile, manage, and submit the technical dossiers required for pathways like the abridged route. To learn how we can accelerate your global expansion, visit us at https://pureglobal.com/, contact [email protected], or explore our FREE AI tools and database at https://pureglobal.ai.

This episode details the mandatory requirement for foreign medical device manufacturers to appoint a Singapore Registrant. We explain the role and responsibilities of this local authorized representative as required by the Health Sciences Authority (HSA), the strategic implications of choosing a representative, and how it impacts market access for Class B, C, and D devices. - What is a Singapore Registrant and why is it mandatory for foreign manufacturers? - Who is eligible to act as a local authorized representative in Singapore? - What are the key legal responsibilities of the company holding the device license? - How does the Registrant control your medical device registration and market access? - Should your distributor also be your Singapore Registrant? - What happens to your HSA registration if you decide to change distributors? - Which medical device risk classes require the appointment of a local Registrant? Pure Global offers expert, independent local representation to act as your Singapore Registrant, ensuring you maintain full control over your device licenses. Our services streamline the HSA registration process, from compiling technical dossiers using advanced AI to managing post-market surveillance. By separating regulatory ownership from distribution, we provide MedTech and IVD companies with the flexibility to scale their business in Singapore and beyond. To secure your market access and build a resilient regulatory strategy, contact us at [email protected], visit https://pureglobal.com/, or explore our FREE AI tools at https://pureglobal.ai/.

This episode provides a detailed guide to the Singapore Health Sciences Authority (HSA) medical device registration pathways for Class B, C, and D devices. We explore the four main evaluation routes—Full, Abridged, Expedited, and Immediate—and explain how leveraging prior approvals from key international reference agencies like the US FDA and EU Notified Bodies can significantly accelerate your product's entry into the Singaporean market. - What are Singapore's four main evaluation routes for medical devices? - How can a US FDA approval or CE Mark speed up your HSA registration? - Which pathway is required for a novel device with no other market approvals? - What are the specific criteria for the Abridged route for Class B, C, and D devices? - Can your high-risk Class C or D device qualify for an Expedited review? - What are the requirements to get a Class B device registered almost immediately? - Which five global regulatory bodies does Singapore's HSA recognize? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies. We act as your local representative in over 30 markets, developing efficient regulatory strategies to get your product approved faster. Our advanced AI and data tools streamline the compilation and submission of technical dossiers, helping you identify the best markets for expansion. Whether you are a startup or a multinational, our integrated approach allows a single registration process to access multiple markets, combining global reach with local expertise. Contact us at [email protected] or visit https://pureglobal.com. Explore our FREE AI tools at https://pureglobal.ai.

This episode provides a detailed guide to Singapore's Health Sciences Authority (HSA) medical device risk classification system. We explore the four-tier structure (Class A to Class D), explain how it aligns with international GHTF/IMDRF principles, and discuss how factors like intended use and invasiveness determine a device's class. Understanding this foundational step is crucial as it dictates the entire regulatory pathway for market access in Singapore. Key Questions: - What are the four risk classes for medical devices in Singapore? - How does the HSA classify a device based on its intended use and technology? - Why is Singapore's system aligned with global standards like the GHTF? - What are some examples of Class A, B, C, and D devices? - How does risk classification impact the registration process and timeline? - What are the consequences of incorrectly classifying your medical device? - Which devices might be exempt from pre-market registration in Singapore? Navigating Singapore's regulatory landscape requires local expertise and strategic planning. Pure Global specializes in helping MedTech and IVD companies achieve market access in over 30 countries, including key Asia Pacific markets like Singapore. Our experts develop efficient regulatory strategies, manage technical dossier submissions, and act as your local representative. By leveraging advanced AI and data tools, we streamline the process, ensuring your device is classified correctly and your submission is optimized for success. Contact Pure Global at [email protected], visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai to accelerate your global expansion.